PHARMACY

Daiichi Sankyo to acquire U3 Pharma for $233.5 million

BY Drew Buono

TOKYO and LONDON Daiichi Sankyo has agreed to purchase the German biotech company U3 Pharma for $233.5 million, in an effort to boost its cancer drug pipeline, according to Reuters. The company said that the acquisition would give it a variety of early-stage fully human antibody programs with potential for treating breast, lung, colorectal and other cancers.

“One of our goals for Daiichi Sankyo is to increase our presence in novel therapeutics in the oncology arena,” Takashi Shoda, the company’s president and chief executive officer, said in a statement. “Our acquisition of U3 Pharma is an ideal strategic fit.”

The most advanced drug in U3’s pipeline is an anti-cancer product, AMG 888, which is being co-developed with Amgen and is due to enter clinical development this year. This goes well with Daiichi’s cancer drug CS-1008, which is in mid-stage phase II tests for malignant neoplasms.

This deal is now becoming part of a trend of Japanese pharmaceutical companies purchasing biotech companies to bolster their own pipeline for the emerging cancer drug market. Takeda Pharmaceuticals last month bought the biotech company Millennium Pharmaceuticals for $8.8 billion, while Eisai spent $3.9 billion to acquire MGI Pharma in December.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

GSK survey finds asthma sufferers lax in controlling condition

BY Drew Buono

RESEARCH TRIANGLE PARK, N.C., and TORONTO According to a new survey conducted by GlaxoSmithKline, nearly half of adult Americans and more than a quarter of children with asthma do not have their disease well controlled.

The Asthma USA survey examined over 81,500 households by using the Asthma Control Test, which assessed asthma control using a questionnaire. Of the more than 10,000 adults that took the ACT, 41 percent had a score of 19 or less, which indicates asthma that is not well controlled.

Children were given the Childhood Asthma Control Test and the ACT to determine their level of asthma control. According to the findings, of the 3,000 children that responded, 31 percent of the children between the ages of 4 and 11 and 25 percent of those between 12 and 17 did not have well-controlled asthma.

The survey also found that asthma that wasn’t well controlled had significant medical consequences. Adults with uncontrolled asthma were more likely to require treatment with oral corticosteroids, visit the emergency department or be admitted to the hospital than those whose asthma was well controlled. Children with uncontrolled asthma were also more likely to require urgent medical care.

“We have made quantum leaps in asthma treatment in the last decade, but the Asthma USA results demonstrate that enormous numbers of patients are living with asthma that is still not well controlled, putting them at significant health risk,” said David Stempel, director of clinical medicine for GlaxoSmithKline. “These findings remind us that improvements in care have not been uniform and underscore the critical need to improve education for both patients and healthcare providers in the management of asthma.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA warns against use of CellCept and Myfortic during pregnancy

BY Drew Buono

WASHINGTON The Food and Drug Administration has again warned that Roche’s CellCept and Novartis’ Myfortic which are prescribed to organ transplant patients can cause miscarriages and birth defects when used by pregnant women, according to published reports. The drugs are used to suppress the body’s immune system to avoid organ rejection in transplant patients

Last October the agency said it had received reports of miscarriages and infants born with ear and mouth birth defects after their mothers took CellCept. At the time, FDA added a black-box warning to CellCept and Myfortic.

The FDA said most of the reported problems came from mothers who were taking CellCept before their pregnancies were detected. Some of the patients were taking the drug for conditions it was not approved to treat including rheumatoid arthritis and lupus.

A spokesman for Roche said it has not received any new reports of miscarriages or birth defects since updating the drug’s labeling. The company previously reported 25 miscarriages among 77 women exposed to the drug between 1995 and 2007.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES